Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are ...

DehydraTECH’s ability to improve oral tolerability could, in future, however, help to drive increased use ... drug delivery into the bloodstream. As this published study notes, the ...

GLP-1 receptor agonist use was associated with a reduced risk of progressing to cirrhosis and related complications in ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...

Related Study shows shift in GLP-1 drug use for obesity, not diabetes Weight loss drug Zepbound outperforms Ozempic in new published study WHO, Eli Lilly warn of fake weight-loss drugs There's one ...

Aon found GLP-1 use cost employer health plans $6.25 per member per month in 2023, a 224% increase compared to 2022. The data on spending for 2024 is not yet available, but a study shows GLP-1 ...

Related Wegovy might lower risk of heart attack, stroke in heart failure patients Study shows shift in GLP-1 drug use for obesity, not diabetes Weight loss drug Zepbound outperforms Ozempic in new ...

As this published study notes, the level of expected weight loss associated with GLP-1 drugs is directly correlated with the ... potential adverse effects arising from the testing or use of products ...

As this published study notes, the level of expected weight loss associated with GLP-1 drugs is directly correlated ... effects arising from the testing or use of products utilizing the ...